ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2057

TLR-7-Mediated Lupus Nephritis Flares Are Independent of Type I Interferon Signaling

Sonya Wolf1, Tamra J. Reed2, Chaim O. Jacob3 and J. Michelle Kahlenberg4, 1Internal Medicine, Division of Rheumatology, University of Michigan Medical School, Ann Arbor, MI, 2Internal Medicine, Rheumatology, University of Michigan, Ann Arbor, MI, 3Medicine/Div of Rheumatology, USC School of Medicine, Los Angeles, CA, 4Internal Medicine, Division of Rheumatology, Division of Rheumatology, University of Michigan Medical Center, Ann Arbor, MI

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: interferons, Nephritis, systemic lupus erythematosus (SLE) and toll-like receptors

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 14, 2016

Title: Systemic Lupus Erythematosus – Animal Models

Session Type: ACR Concurrent Abstract Session

Session Time: 4:30PM-6:00PM

Background/Purpose: Systemic Lupus Erythematosus (SLE) is an autoimmune disease characterized by the formation of autoantibodies, immune complex deposition, elevated production of type I interferons (IFNs), and inflammatory-mediated multi-organ damage. Lupus nephritis (LN) flares contribute to high mortality and morbidity among patients. Activation of endosomal toll-like receptor (TLR) 7 is an important trigger of LN activity. Stimulation of TLR7 leads to type I interferon (IFN) production and nuclear factor kappaB (NFkB) activation. Type I IFNs are important for TLR7-mediated immunoproliferation, but their role in TLR7-mediated nephritis has not been examined. This study explores the novel hypothesis that TLR7 promotion of lupus nephritis is independent of type I IFNs.

Methods: To address this hypothesis, we use the lupus prone NZM 2328 and iNZM (NZM2328 lacking a functional type I IFN receptor) murine models. In order to induce LN flares, we administered 100μg of R848 (TLR 7 agonist) epicutaneously to the right ear or intraperitoneally (IP) to 10-week old female NZM2328 and iNZM mice thrice weekly. Serum was collected from mice every 2 weeks and urine collected every week. Mice were harvested at 14 days or at LN onset. Double stranded DNA antibodies were quantified via ELISA. Immunofluorescence for C3 and IgG was performed on kidney tissue to examine the extent of immune complex deposition. Flow cytometry was used to characterize the immune cell populations in the kidney for both strains. Real-time qPCR was performed to examine gene expression in the kidney following R848 treatment.

Results: Lymphoproliferative response to R848 was absent in iNZM mice, consistent with previous reports. Notably, both NZM2328 and iNZM mice exhibit a decline in survival after 3 to 4 weeks of R848 treatment. This decline was significantly more robust with epicutaneous vs. IP injection of R848. Both NZM and iNZM mice demonstrated equivalent acceleration of lupus characteristics including: rise in dsDNA antibodies, increased kidney immune complex deposition, and development of proteinuria. They also demonstrated infiltration of the kidney by macrophages and dendritic cells 2 weeks into treatment. Transcriptional changes within the kidney identified upregulation of inflammasome-associated genes as a shared response in both NZM2328 and iNZM mice after R848 treatment.

Conclusion: The development of TLR7-mediated lupus nephritis flares occurs independent of type I IFN signaling. Further investigation into the role of the inflammasome in mediating TLR7-driven lupus is key to development of novel therapies which may prevent lupus nephritis flare induction.


Disclosure: S. Wolf, None; T. J. Reed, None; C. O. Jacob, None; J. M. Kahlenberg, None.

To cite this abstract in AMA style:

Wolf S, Reed TJ, Jacob CO, Kahlenberg JM. TLR-7-Mediated Lupus Nephritis Flares Are Independent of Type I Interferon Signaling [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/tlr-7-mediated-lupus-nephritis-flares-are-independent-of-type-i-interferon-signaling/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/tlr-7-mediated-lupus-nephritis-flares-are-independent-of-type-i-interferon-signaling/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology